DOP2024000275A - Compuestos de pirido[4,3-d]pirimidina - Google Patents
Compuestos de pirido[4,3-d]pirimidinaInfo
- Publication number
- DOP2024000275A DOP2024000275A DO2024000275A DO2024000275A DOP2024000275A DO P2024000275 A DOP2024000275 A DO P2024000275A DO 2024000275 A DO2024000275 A DO 2024000275A DO 2024000275 A DO2024000275 A DO 2024000275A DO P2024000275 A DOP2024000275 A DO P2024000275A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pyrido
- pyrimidine compounds
- compounds
- processes
- amelioration
- Prior art date
Links
- 159000000015 pyrido[4,3-d]pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263358324P | 2022-07-05 | 2022-07-05 | |
| US202263394338P | 2022-08-02 | 2022-08-02 | |
| US202263414939P | 2022-10-11 | 2022-10-11 | |
| US202363502931P | 2023-05-18 | 2023-05-18 | |
| PCT/IB2023/056844 WO2024009191A1 (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000275A true DOP2024000275A (es) | 2025-01-31 |
Family
ID=87426656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000275A DOP2024000275A (es) | 2022-07-05 | 2024-12-30 | Compuestos de pirido[4,3-d]pirimidina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4551296A1 (https=) |
| JP (1) | JP2025525406A (https=) |
| KR (1) | KR20250029954A (https=) |
| CN (1) | CN119585286A (https=) |
| AU (1) | AU2023302139A1 (https=) |
| CA (1) | CA3261000A1 (https=) |
| CL (1) | CL2024003699A1 (https=) |
| CO (1) | CO2024016875A2 (https=) |
| CR (1) | CR20240556A (https=) |
| DO (1) | DOP2024000275A (https=) |
| IL (1) | IL317957A (https=) |
| MA (1) | MA71388A (https=) |
| MX (1) | MX2024015001A (https=) |
| PE (1) | PE20250259A1 (https=) |
| PY (1) | PY2352053A (https=) |
| TW (2) | TW202513571A (https=) |
| WO (1) | WO2024009191A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| JP2024543879A (ja) * | 2021-11-24 | 2024-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ変異型タンパク質の小分子阻害剤 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| CN120282969A (zh) * | 2022-11-17 | 2025-07-08 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024209339A1 (en) | 2023-04-05 | 2024-10-10 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4713330A1 (en) * | 2023-05-16 | 2026-03-25 | HUTCHMED Limited | Tricyclic compounds and uses thereof |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| TW202527946A (zh) * | 2023-12-19 | 2025-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 三并環類化合物及其醫藥用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025228381A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugate and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN119874616B (zh) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | 一种有机中间体及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| AR088061A1 (es) | 2011-09-27 | 2014-05-07 | Hoffmann La Roche | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso |
| MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| PL3988117T3 (pl) | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| CN110191652B (zh) | 2016-11-16 | 2023-04-28 | 温克机器人技术公司 | 用于自动睫毛延长的眼睑覆盖和稳定 |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| CN118772278A (zh) | 2017-06-02 | 2024-10-15 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| US20220251109A1 (en) * | 2019-04-28 | 2022-08-11 | Genfleet Therapeutics (Shanghai) Inc. | Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| WO2022132200A1 (en) * | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
-
2023
- 2023-06-30 MA MA71388A patent/MA71388A/fr unknown
- 2023-06-30 JP JP2024576355A patent/JP2025525406A/ja active Pending
- 2023-06-30 KR KR1020257003513A patent/KR20250029954A/ko active Pending
- 2023-06-30 CR CR20240556A patent/CR20240556A/es unknown
- 2023-06-30 IL IL317957A patent/IL317957A/en unknown
- 2023-06-30 CA CA3261000A patent/CA3261000A1/en active Pending
- 2023-06-30 WO PCT/IB2023/056844 patent/WO2024009191A1/en not_active Ceased
- 2023-06-30 EP EP23744558.0A patent/EP4551296A1/en active Pending
- 2023-06-30 AU AU2023302139A patent/AU2023302139A1/en active Pending
- 2023-06-30 PE PE2024002870A patent/PE20250259A1/es unknown
- 2023-06-30 CN CN202380051793.7A patent/CN119585286A/zh active Pending
- 2023-07-04 TW TW113147938A patent/TW202513571A/zh unknown
- 2023-07-04 PY PY202302352053A patent/PY2352053A/es unknown
- 2023-07-04 TW TW112124839A patent/TWI869913B/zh active
-
2024
- 2024-12-02 CL CL2024003699A patent/CL2024003699A1/es unknown
- 2024-12-03 MX MX2024015001A patent/MX2024015001A/es unknown
- 2024-12-09 CO CONC2024/0016875A patent/CO2024016875A2/es unknown
- 2024-12-30 DO DO2024000275A patent/DOP2024000275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4551296A1 (en) | 2025-05-14 |
| PE20250259A1 (es) | 2025-01-29 |
| CR20240556A (es) | 2025-01-29 |
| TWI869913B (zh) | 2025-01-11 |
| MX2024015001A (es) | 2025-01-09 |
| JP2025525406A (ja) | 2025-08-05 |
| PY2352053A (es) | 2025-03-06 |
| CL2024003699A1 (es) | 2025-04-11 |
| TW202513571A (zh) | 2025-04-01 |
| KR20250029954A (ko) | 2025-03-05 |
| CO2024016875A2 (es) | 2024-12-19 |
| WO2024009191A1 (en) | 2024-01-11 |
| MA71388A (fr) | 2025-04-30 |
| AU2023302139A1 (en) | 2024-12-19 |
| CA3261000A1 (en) | 2024-01-11 |
| TW202409047A (zh) | 2024-03-01 |
| CN119585286A (zh) | 2025-03-07 |
| IL317957A (en) | 2025-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000275A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| DOP2025000250A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| AR127050A1 (es) | Compuestos espirocíclicos | |
| CL2021002296A1 (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| CO2024015229A2 (es) | Compuestos y usos de estos | |
| UY28343A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| DOP2005000006A (es) | "derivados de sulfonamida para el tratamiento de enfermedades" | |
| DOP2024000239A (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| CR20190429A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| DOP2025000099A (es) | Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos | |
| CO2025014389A2 (es) | Derivados de amida para inhibir nlrp3 y usos de estos | |
| CO2024000083A2 (es) | Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica | |
| CO2024015686A2 (es) | Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer | |
| AR134577A1 (es) | Compuestos de bifenilo y fenilpiridina | |
| AR134411A1 (es) | Compuestos de uracilo | |
| AR133191A1 (es) | Adyuvantes anfifilicos tlr7/8 y usos de estos | |
| ECSP045055A (es) | 2-amino-6- (fenilo sustituido en las posiciones 2,4,5) -piridinas | |
| MX2024013840A (es) | Derivados de pirazina y usos de los mismos | |
| CL2025001386A1 (es) | Compuestos derivados de hexahidropirano[3',4':4,5]pirrolo[2,3-d]pirimidina y uso para tratar cáncer. | |
| MX2024013841A (es) | Derivados de pirazina y usos de estos | |
| AR131335A1 (es) | Enlazadores-cargas útiles de auristatina, composiciones farmacéuticas, y usos de los mismos | |
| PY2003748A (es) | Inhibidores de inflamasoma nlrp3 |